Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

What Hedge Fund Sentiment Says About Pieris Pharmaceuticals Inc (PIRS) And Its Peers

The successful funds run by legendary investors such as Dan Loeb and David Tepper make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don’t follow. Because of their pay structures, they have strong incentive to do the research necessary to beat the market. That’s why we pay close attention to what they think in small cap stocks. In this article, we take a closer look at Pieris Pharmaceuticals Inc (NASDAQ:PIRS) from the perspective of those successful funds.

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) was in 6 hedge funds’ portfolios at the end of the third quarter of 2016. PIRS investors should pay attention to an increase in hedge fund sentiment lately. There were 5 hedge funds in our database with PIRS holdings at the end of the second quarter. At the end of this article we will also compare PIRS to other stocks including Rocky Brands, Inc. (NASDAQ:RCKY), Arotech Corporation (NASDAQ:ARTX), and North American Energy Partners Inc.(USA) (NYSE:NOA) to get a better sense of its popularity.

Follow Pieris Pharmaceuticals Inc. (NYSE:PIRS)
Trade (NYSE:PIRS) Now!

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

Abbvie ABBV biopharmaceuticals cell blood dna gene stem test biotech research


Hedge fund activity in Pieris Pharmaceuticals Inc (NASDAQ:PIRS)

Heading into the fourth quarter of 2016, a total of 6 of the hedge funds tracked by Insider Monkey were bullish on this stock, a 20% gain from one quarter earlier, and the fourth-straight quarter in which hedge fund ownership has increased by exactly 1 fund. With hedgies’ capital changing hands, there exists a select group of notable hedge fund managers who were boosting their stakes significantly (or already accumulated large positions).


Of the funds tracked by Insider Monkey, OrbiMed Advisors, led by Samuel Isaly, holds the most valuable position in Pieris Pharmaceuticals Inc (NASDAQ:PIRS). OrbiMed Advisors has a $13.3 million position in the stock. Sitting at the No. 2 spot is Sabby Capital, led by Hal Mintz, which holds a $2.8 million position. Some other professional money managers with similar optimism encompass Mark Lampert’s Biotechnology Value Fund, Nathan Fischel’s DAFNA Capital Management, and Renaissance Technologies, one of the largest hedge funds in the world. We should note that none of these hedge funds are among our list of the 100 best performing hedge funds, which is based on the performance of their 13F long positions in non-micro-cap stocks.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.